Hegedüs L - Search Results

1

Smith TJ, Hegedüs L. Smith TJ, et al. Among authors: hegedus l. N Engl J Med. 2016 Oct 20;375(16):1552-1565. doi: 10.1056/NEJMra1510030. N Engl J Med. 2016. PMID: 27797318 Review. No abstract available.

2

Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease.

Jensen BE, Bonnema SJ, Hegedüs L. Jensen BE, et al. Among authors: hegedus l. Eur J Endocrinol. 2005 Jul;153(1):15-21. doi: 10.1530/eje.1.01924. Eur J Endocrinol. 2005. PMID: 15994741

3

The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option.

El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hegedus l. Eur J Endocrinol. 2006 May;154(5):623-32. doi: 10.1530/eje.1.02140. Eur J Endocrinol. 2006. PMID: 16645007 Review.

4

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.

El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. El Fassi D, et al. Among authors: hegedus l. J Clin Endocrinol Metab. 2007 May;92(5):1769-72. doi: 10.1210/jc.2006-2388. Epub 2007 Feb 6. J Clin Endocrinol Metab. 2007. PMID: 17284622 Clinical Trial.

5

Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease.

El Fassi D, Clemmensen O, Nielsen CH, Silkiss RZ, Hegedüs L. El Fassi D, et al. Among authors: hegedus l. J Clin Endocrinol Metab. 2007 Oct;92(10):3762-3. doi: 10.1210/jc.2007-1238. J Clin Endocrinol Metab. 2007. PMID: 17933978 No abstract available.

6

Too early to dismiss Yersinia enterocolitica infection in the aetiology of Graves' disease: evidence from a twin case-control study.

Brix TH, Hansen PS, Hegedüs L, Wenzel BE. Brix TH, et al. Among authors: hegedus l. Clin Endocrinol (Oxf). 2008 Sep;69(3):491-6. doi: 10.1111/j.1365-2265.2008.03227.x. Epub 2008 Feb 18. Clin Endocrinol (Oxf). 2008. PMID: 18284638

7

Divergent frequencies of IGF-I receptor-expressing blood lymphocytes in monozygotic twin pairs discordant for Graves' disease: evidence for a phenotypic signature ascribable to nongenetic factors.

Douglas RS, Brix TH, Hwang CJ, Hegedüs L, Smith TJ. Douglas RS, et al. Among authors: hegedus l. J Clin Endocrinol Metab. 2009 May;94(5):1797-802. doi: 10.1210/jc.2008-2810. Epub 2009 Feb 24. J Clin Endocrinol Metab. 2009. PMID: 19240157 Free PMC article.

8

Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities.

Hegedüs L. Hegedüs L. Endocrinol Metab Clin North Am. 2009 Jun;38(2):355-71, ix. doi: 10.1016/j.ecl.2009.01.009. Endocrinol Metab Clin North Am. 2009. PMID: 19328416 Review.

9

Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Douglas RS, Tsirbas A, Gordon M, Lee D, Khadavi N, Garneau HC, Goldberg RA, Cahill K, Dolman PJ, Elner V, Feldon S, Lucarelli M, Uddin J, Kazim M, Smith TJ, Khanna D; International Thyroid Eye Disease Society. Douglas RS, et al. Arch Ophthalmol. 2009 Sep;127(9):1155-60. doi: 10.1001/archophthalmol.2009.232. Arch Ophthalmol. 2009. PMID: 19752424 Free PMC article.

10

Optimizing remission rates using antithyroid drugs for Graves' disease.

Hegedüs L. Hegedüs L. Clin Endocrinol (Oxf). 2010 Jun;72(6):729-30. doi: 10.1111/j.1365-2265.2009.03778.x. Epub 2009 Dec 29. Clin Endocrinol (Oxf). 2010. PMID: 20050856 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

633 results

Search Page